NLX-101, a highly selective 5-HT1A receptor biased agonist, mediates antidepressant-like activity in rats via prefrontal cortex 5-HT1A receptors
| Autor: | Ronan Depoortère, Agnès L. Auclair, Adrian Newman-Tancredi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Agonist
0303 health sciences medicine.medical_specialty medicine.drug_class Chemistry Receptor antagonist 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Endocrinology nervous system Internal medicine medicine 5-HT1A receptor Serotonin Prefrontal cortex Receptor NLX 030217 neurology & neurosurgery 030304 developmental biology Behavioural despair test |
| Zdroj: | Behavioural Brain Research. 401:113082 |
| ISSN: | 0166-4328 |
| DOI: | 10.1016/j.bbr.2020.113082 |
| Popis: | NLX-101 (also known as F15599) exhibits nanomolar affinity, exceptional selectivity and biased agonist activation of serotonin 5-HT1A receptors. Given systemically, it displays antidepressant-like activity in the rat forced swim test (FST), and preferentially activates 5-HT1A post-synaptic heteroreceptors in the prefrontal cortex (PFC), a brain region involved in the control of mood. Here, we assessed the ability of NLX-101 to produce antidepressant-like activity in the FST following in-situ PFC unilateral microinjection. (+)8-OH-DPAT and F13714, two 5-HT1A receptor agonists that do not display cortical biased agonism, were tested as comparators. NLX-101 decreased time spent in immobility in a bi-modal manner, with a first MED of 0.25 μg (immobility reduced from 160 to 80 s) but immobility returned to control levels at the next dose (1 μg). At higher doses, immobility decreased monotonically, with a second MED of 16 μg and a maximal effect (36 s) at 32 μg. (+)8-OH-DPAT and F13714 also diminished immobility but, unlike NLX-101, they did so in a unimodal manner, with MEDs of 1 and 4 μg, and maximal responses of 31 and 4 s, for (+)8-OH-DPAT and F13714, respectively. The effects of (+)8-OH-DPAT (16 μg) and of both active doses of NLX-101 (0.25 and 16 μg) were prevented by the 5-HT1A receptor antagonist WAY-100,635 (0.63 mg/kg s.c.). In conclusion, activation of 5-HT1A receptors in the PFC by NLX-101 produces robust antidepressant-like effects in the rat FST, with a distinctive bimodal dose-response pattern. These data suggest that NLX-101 may target specific 5-HT1A receptor subpopulations in PFC, likely located on GABAergic and/or glutamatergic neurons. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect